News und Analysen
Almirall: Ilumetri® (tildrakizumab) significantly improved the wellbeing of patients with moderate-to-severe plaque psoriasis
Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced that Ilumetri® (tildrakizumab) significantly improved wellbeing in patients with
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Acadia Healthcare Announces Date for Second Quarter 2023 Earnings Release
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its second quarter 2023 results on Thursday, July 27, 2023, after the close of the market. Acadia will conduct a
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Invitation to Cosmo’s Half-Year 2023 Webcast on 26 July 2023
Novocure to Report Second Quarter 2023 Financial Results
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2023 on Thursday, July 27, 2023, before the U.S. financial markets open. Novocure management
Acadia Healthcare Forms Joint Venture Partnership with SolutionHealth in New Hampshire
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) announced today that it has formed a joint venture with SolutionHealth to build a modern 144-bed behavioral health hospital in southeast New Hampshire
SolutionHealth and Acadia Healthcare Form Joint Venture to Build a Behavioral Health Hospital in Southeast New Hampshire
The Board of Trustees of SolutionHealth, parent organization of Elliot Health System and Southern New Hampshire Health, has formed a joint venture with Acadia Healthcare, a leading provider of
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Cosmo announces the beginning of the phase III trials in males for the treatment of androgenetic alopecia
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
ICON plc Schedules Second Quarter 2023 Earnings Conference Call
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the second quarter 2023 after the
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
ICON Releases Latest Version of its Digital Platform, Providing Integrated Patient Services and Harmonised Data in One Platform
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced the latest release of its Digital Platform. The platform supports seamless
ICON plc Set to Join Russell 3000® Index
ICON plc, (NASDAQ: ICLR), is set to join the broad-market Russell 3000® Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens today, Monday
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Premier, Inc. Honors Program that Helps Low-Income Seniors Age in Place with National Award and $100,000 Donation
Aging Gracefully, a nonprofit program dedicated to making homes safer for low-income adults over the age of 65, has received the 2023 Premier Cares Award and a $100,000 cash prize from Premier,
Cosmo and Hyundai Pharm Announce Signing of License Agreement for Winlevi® in Korea
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
WakeMed Health & Hospitals Wins 2023 Premier Alliance Excellence Award
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, has named WakeMed Health & Hospitals, a nationally recognized 970-bed not-for-profit healthcare system
Almirall launches Nina, the first series to highlight the major impact of psoriasis on patient’s wellbeing
Psoriasis is a chronic dermatological disease that not only affects the skin but also their mental and social wellbeing. The disease has an impact on all aspects of daily lives and almost 77% of
Cosmo Pharmaceuticals announces approval of Winlevi® in Canada
Sonova further extends offering of Sennheiser-branded hearing solutions with All-Day Clear
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc